Nanocoating with titanium reduces iC3b- and granulocyte-activating immune response against glutaraldehyde-fixed bovine pericardium: A new technique to improve biologic heart valve prosthesis durability?

Journal of Thoracic and Cardiovascular Surgery

Volumn 143, Issue 5, 2012, Pages 1152-1159

  Guldner, Norbert W ^a   Bastian, Fabienne ^b   Weigel, Günther ^b   Zimmermann, Hanngörg ^c   Maleika, Markus ^c   Scharfschwerdt, Michael ^a   Rohde, Daniel ^a   Sievers, Hans Hinrich ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Pfm Titanium GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; GLUTARALDEHYDE; IMMUNOGLOBULIN G; NANOCOATING; TITANIUM;

ANIMAL TISSUE; ARTICLE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; COW; GRANULOCYTE; HEART VALVE PROSTHESIS; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE ACTIVATION; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

ANIMALS; BIOPROSTHESIS; CATTLE; COATED MATERIALS, BIOCOMPATIBLE; COMPLEMENT C3B; FIXATIVES; GLUTARAL; GRAFT REJECTION; GRAFT SURVIVAL; GRANULOCYTES; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; MATERIALS TESTING; MICROSCOPY, ELECTRON, SCANNING; NANOTECHNOLOGY; ORGANOMETALLIC COMPOUNDS; PERICARDIUM; PROSTHESIS FAILURE; TISSUE FIXATION;

EID: 84859778184     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2011.10.076     Document Type: Article

References (30)

1. Ueyama K, Kamiya H, Kanamori T, Ohashi H, Yasushi T, Kawai T, et al. Long-term follow-up of cardiac valve replacement using bioprosthesis in patients 70 years old and older. Artif Organs. 2002;26:1059-62. (Pubitemid 41764139)
2. Carpentier A, Lemaigre G, Robert L, Carpentier S, Dubost C, Gerbode F. Biological factors affecting long-term results of valvular heterografts. J Thorac Cardiovasc Surg. 1969;58:467-83.
3. Williams DB, Danielson GK, McGoon DC, Puga FJ, Mair DD, Edwards WD. Porcine heterograft valve replacement in children. J Thorac Cardiovasc Surg. 1982;84:446-50. (Pubitemid 13096750)
4. Simionescu DT. Prevention of calcification in bioprosthetic heart valves: Challenges and perspectives. Expert Opin Biol Ther. 2004;4:1971.
5. Rocchini AP, Weesner KM, Heidelberger K, Keren D, Behrendt D, Rosenthal A. Porcine xenograft valve failure in children: an immunologic response. Circulation. 1981;64:II162-71.
6. Rizwan AM, Zhu LF, Nijjar NK, Rayner DC, Korbutt GS, Churchill TA, et al. Glutaraldehyde-fixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection. Circulation. 2006;114:318-27. (Pubitemid 44297098)
7. Dahm M, Lyman WD, Schwell AB, Factor SM, Frater RW. Immunogenicity of glutaraldehyde-tanned bovine pericardium. J Thorac Cardiovasc Surg. 1990;99: 1082-90. (Pubitemid 20209411)
8. Fischbein MP, Ardehali A, Yun J, Schoenberger S, Laks H, Irie Y, et al. CD40 signaling replaces CD4+lymphocytes and its blocking prevents chronic rejection of heart transplants. J Immunol. 2000;165:7316-22. (Pubitemid 32001212)
9. Juthier F, Vincentelli A, Gaudric J, Corseaux D, Fouquet O, Calet C, et al. Decellularized heart valve as a scaffold for in vivo recellularization: Deleterious effects of granulocyte colony-stimulating factor. J Thorac Cardiovasc Surg. 2006;131:843-52.
10. Rieder E, Nigisch A, Dekan B, Kasimir MT, Mühlbacher F, Wolner E, et al. Granulocyte- based immune response against decellularized or glutaraldehyde cross-linked vascular tissue. Biomaterials. 2006;27:5634-42. (Pubitemid 44279060)
11. Bastian F, Stelzmüller ME, Kratochwill K, Kasimir MT, Simon P, Weigel G. IgG deposition and activation of the classical complement pathway involvement in the activation of human granulocytes by decellularized porcine heart valve tissue. Biomaterials. 2008;29:1824-32.
12. Sayk F, Inge Bos I, Schubert U, Wedel T, Sievers H-H. Histopathologic findings in a novel decellularized pulmonary homograft: An autopsy study. Ann Thorac Surg. 2005;79:1755-8. (Pubitemid 40614605)
13. Simon P, Kasimir MT, Seebacher G,Weigel G, Ullrich R, Salzer-Muhar U, et al. Early failure of the tissue engineered porcine heart valve Synergraft in pediatric patients. Eur J Cardiothorac Surg. 2003;23:1002-6. (Pubitemid 36794083)
14. Guldner NW, Jasmund I, Zimmermann H, Heinlein M, Girndt B, Meier V, et al. Detoxification and endothelialization of glutaraldehyde-fixed bovine pericardium with titanium coating. Circulation. 2009;119:1653-60.
15. Guldner NW, Jasmund I, Zimmermann H, Heinlein M, Girndt B, Großherr M, et al. The first self-endothelialized titanium coated glutaraldehyde-fixed heart valve prosthesis within systemic circulation. J Thorac Cardiovasc Surg. 2009;138:248-50.
16. Gulbins H, Goldemund A, Anderson I. Preseeding with autologous fibroblasts improves endothelialization of glutaraldehyde-fixed porcine aortic valves. J Thorac Cardiovasc Surg. 2003;125:592-601. (Pubitemid 36373905)
17. Gulbins H, Pritisanac A, Anderson I. Myoblasts survive for 16 weeks after intracardiac transfer and start differentiation. Thorac Cardiovasc Surg. 2003;51: 295-300. (Pubitemid 38031383)
18. Sivaram S. Chemical Vapor Deposition: Thermal and Plasma Deposition of Electronic Materials. New York: Van Nostrand Reinhold; 1995.
19. Grill A. Cold Plasma in Materials Fabrication: From Fundamentals to Applications. New York: IEEE Press; 1994.
20. Dag B, ed. Surface Characterization. Weinheim: Wiley-VCH; 1997.
21. Nilsson UR. Deposition of C3b/iC3b leads to the concealment of antigens, immunoglobulins and bound C1q in complement-activating immune complexes. Mol Immunol. 2001;38:151-60. (Pubitemid 32786773)
22. Gemmell CH, Black JP, Yeo EL, Sefton MV. Material-induced up-regulation of leukocyte CD11b during whole blood contact: Material differences and a role for complement. J Biomed Mater Res. 1996;32:29-35. (Pubitemid 26272338)
23. Gorbet B, Sefton MV. Complement inhibition reduces material-induced leukocyte activation with PEG modified polystyrene beads (Tentagel™) but not polystyrene beads. J Biomed Materials Res. 2005;74A:511-22. (Pubitemid 41216253)
24. Galili U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: A major obstacle for xenotransplantation in humans. Immunol Today. 1993;14:480-2. (Pubitemid 23300997)
25. Konakci KZ, Bohle B, Blumer R, Hoetzenecker W, Roth G, Moser B. Alpha-galon bioprostheses: Xenograft immune response in cardiac surgery. Eur J Clin Invest. 2005;35:17-23. (Pubitemid 40187950)
26. Hoerstrup SP, Kadner A, Melnitchouk S. Tissue engineering of functional trileaflet heart valves from human marrow stromal cells. Circulation. 2002;106:143-50.
27. Bader A, Schlilling T, Teebken OE. Tissue engineering of heart valves - Human endothelial cell seeding of detergent acellularized porcine valves. Eur J Cardiothorac Surg. 1998;14:279-84. (Pubitemid 28417083)
28. Fischlein T, Fasol R. In vitro endothelialization of bioprosthetic heart valves. J Heart Valve Dis. 1996;5:58-65. (Pubitemid 26060687)
29. Rieder E, Kasimir M, Silberhumer G, Seebacher G, Wolner E, Simon P, et al. Decellularization protocols of porcine heart valves differ importantly in efficiency of cell removal and susceptibility of the matrix to recellularization with human vascular cells. J Thorac Cardiovasc Surg. 2004;127:399-405. (Pubitemid 38176643)
30. Schoen FJ, Hirsch D, Bianco RW, Levy RJ. Onset and progression of calcification in porcine aortic bioprosthetic valves implanted as orthotopic mitral valve replacements in juvenile sheep. J Thorac Cardiovasc Surg. 1994;108:880-7. (Pubitemid 24351672)